HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Sun Pharmaceutical Industries gains after its arm gets nod to set up greenfield project
Dec-03-2025

Sun Pharmaceutical Industries is currently trading at Rs 1808.70, up by 10.65 points or 0.59% from its previous closing of Rs 1798.05 on the BSE.

The scrip opened at Rs 1802.95 and has touched a high and low of Rs 1815.95 and Rs 1784.00 respectively. So far 42515 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1910.00 on 31-Dec-2024 and a 52-week low of Rs 1547.25 on 26-Sep-2025.

Last one week high and low of the scrip stood at Rs 1843.95 and Rs 1784.00 respectively. The current market cap of the company is Rs 433295.90 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.78% and 8.73% respectively.

Sun Pharmaceutical Industries’ wholly-owned subsidiary – Sun Pharma Laboratories has received approval from Board of Directors for an investment of Rs 3,000 crore for setting up a greenfield formulations manufacturing facility in Madhya Pradesh.

Earlier, the company had launched its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

  RELATED NEWS >>